Literature DB >> 20089450

Lessons learned from natural infection: focusing on the design of protective T cell vaccines for HIV/AIDS.

Jeffrey D Ahlers1, Igor M Belyakov.   

Abstract

CD8(+) cytotoxic T lymphocyte (CTL) responses are crucial in establishing the control of persistent virus infections. Population studies of HIV-1-infected individuals suggest that CD8(+) CTL responses targeting epitopes that take the greatest toll on virus replication are instrumental in immune control. A major question for vaccine design is whether incorporating epitopes responsible for controlling a persistent virus will translate into protection from natural infection or serve solely as a fail-safe mechanism to prevent overt disease in infected individuals. Here, we discuss qualitative parameters of the CD8(+) CTL response and mechanisms operative in the control of persistent virus infections and suggest new strategies for design and delivery of HIV vaccines. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20089450     DOI: 10.1016/j.it.2009.12.003

Source DB:  PubMed          Journal:  Trends Immunol        ISSN: 1471-4906            Impact factor:   16.687


  13 in total

1.  For protection from HIV-1 infection, more might not be better: a systematic analysis of HIV Gag epitopes of two alleles associated with different outcomes of HIV-1 infection.

Authors:  Ma Luo; Christina A Daniuk; Tamsir O Diallo; Rupert E Capina; Joshua Kimani; Charles Wachihi; Makubo Kimani; Thomas Bielawny; Trevor Peterson; Mark G R Mendoza; Sandra Kiazyk; T Blake Ball; Francis A Plummer
Journal:  J Virol       Date:  2011-11-09       Impact factor: 5.103

2.  Sublingual administration of an adenovirus serotype 5 (Ad5)-based vaccine confirms Toll-like receptor agonist activity in the oral cavity and elicits improved mucosal and systemic cell-mediated responses against HIV antigens despite preexisting Ad5 immunity.

Authors:  Daniel M Appledorn; Yasser A Aldhamen; Sarah Godbehere; Sergey S Seregin; Andrea Amalfitano
Journal:  Clin Vaccine Immunol       Date:  2010-11-17

3.  IL-2 complex treatment can protect naive mice from bacterial and viral infection.

Authors:  Sara E Hamilton; Jason M Schenkel; Adovi D Akue; Stephen C Jameson
Journal:  J Immunol       Date:  2010-10-29       Impact factor: 5.422

4.  Conservation of HIV-1 T cell epitopes across time and clades: validation of immunogenic HLA-A2 epitopes selected for the GAIA HIV vaccine.

Authors:  Lauren Levitz; Ousmane A Koita; Kotou Sangare; Matthew T Ardito; Christine M Boyle; John Rozehnal; Karamoko Tounkara; Sounkalo M Dao; Youssouf Koné; Zoumana Koty; Soren Buus; Leonard Moise; William D Martin; Anne S De Groot
Journal:  Vaccine       Date:  2012-10-24       Impact factor: 3.641

Review 5.  Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs.

Authors:  Christine Katlama; Steven G Deeks; Brigitte Autran; Javier Martinez-Picado; Jan van Lunzen; Christine Rouzioux; Michael Miller; Stefano Vella; Joern E Schmitz; Jeffrey Ahlers; Douglas D Richman; Rafick P Sekaly
Journal:  Lancet       Date:  2013-03-29       Impact factor: 79.321

Review 6.  GUCY2C-targeted cancer immunotherapy: past, present and future.

Authors:  Adam E Snook; Michael S Magee; Scott A Waldman
Journal:  Immunol Res       Date:  2011-12       Impact factor: 2.829

7.  Lack of IL-7 and IL-15 signaling affects interferon-γ production by, more than survival of, small intestinal intraepithelial memory CD8+ T cells.

Authors:  Dmitry Isakov; Amiran Dzutsev; Jay A Berzofsky; Igor M Belyakov
Journal:  Eur J Immunol       Date:  2011-12       Impact factor: 5.532

Review 8.  Stem cell-based approaches to treating HIV infection.

Authors:  Scott G Kitchen; Jerome A Zack
Journal:  Curr Opin HIV AIDS       Date:  2011-01       Impact factor: 4.283

9.  In vivo suppression of HIV by antigen specific T cells derived from engineered hematopoietic stem cells.

Authors:  Scott G Kitchen; Bernard R Levin; Gregory Bristol; Valerie Rezek; Sohn Kim; Christian Aguilera-Sandoval; Arumugam Balamurugan; Otto O Yang; Jerome A Zack
Journal:  PLoS Pathog       Date:  2012-04-12       Impact factor: 6.823

10.  Controlling the HIV/AIDS epidemic: current status and global challenges.

Authors:  Thorsten Demberg; Marjorie Robert-Guroff
Journal:  Front Immunol       Date:  2012-08-14       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.